Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tenax Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TENX
Nasdaq
8731
http://www.tenaxthera.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tenax Therapeutics Inc
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
- Apr 9th, 2024 12:30 pm
TENX: 2023 Financial Results
- Apr 9th, 2024 9:38 am
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
- Mar 28th, 2024 12:30 pm
Tenax Therapeutics to Present at the 36th Annual Roth Conference
- Mar 12th, 2024 12:30 pm
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
- Feb 29th, 2024 2:00 pm
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
- Feb 20th, 2024 1:30 pm
TENX: First Patient Enrolled
- Feb 12th, 2024 11:20 am
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
- Feb 8th, 2024 1:16 pm
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
- Feb 8th, 2024 1:01 am
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
- Feb 6th, 2024 1:30 pm
Breakeven On The Horizon For Tenax Therapeutics, Inc. (NASDAQ:TENX)
- Jan 3rd, 2024 1:44 pm
Tenax Therapeutics Announces Reverse Stock Split
- Dec 29th, 2023 1:30 pm
TENX: IND Clears Way for Phase III
- Nov 20th, 2023 12:05 pm
Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board
- Nov 17th, 2023 1:30 pm
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023
- Nov 13th, 2023 1:30 pm
TENX: Second Quarter Results
- Aug 28th, 2023 12:20 pm
7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot Pole
- Aug 25th, 2023 11:20 am
Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
- Jul 19th, 2023 12:30 pm
TENX: Notice of Allowance Increases Confidence
- Jun 23rd, 2023 10:24 am
Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
- May 31st, 2023 12:54 pm
Scroll